Teva Acquires Actavis Generics

Joining forces to build our new future
Teva Acquires Actavis Generics

At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future.

The acquisition delivers on these objectives, while enabling us to take a leading position in our transforming industry.

This strategic acquisition brings together two leading generics businesses with complementary strengths, brands and cultures, providing patients with more affordable access to quality medicines, and creating significant financial benefits for Teva stockholders.

Our newly combined company offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale.

Read more in the press release

Actavis Regional Contacts

Teva welcomes our Actavis Generics local markets. We want to ensure that each region continues to receive the support it needs during this time of transition. Please see the following table for Actavis business regional contact information.



General inquiries
Tel: (65) 65090403

Actavis site

Media relations
Iris Beck Codner, - +972-3-9267208 (Israel) or
Denise Bradley, 215-591-8974 (United States)

Investor relations
Kevin C. Mannix, 215-591-8912 (United States) or
Ran Meir, 215-591-3033 (United States) or
Tomer Amitai, 972 (3) 926-7656 (Israel)